Industry / Spain

More Gloom For Drugmakers

May 2010 | Industry Trend Analysis

Printable version
Bookmark

BMI Core View: The introduction of government price erosion mechanisms will accelerate across Europe, driven by the need for fiscal austerity and presaged by the actions of numerous governments over the past six months.

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles

Generic Medicines Industry Association Puts Forward Recommendations To Push Market Sector

Industry / Spain Highlighting Spain as having one of the lowest levels of generic medicines uptake in Europe, the country's generic medicine industry association, AESEG, has put forward key recommendations to stimulate...

October 2009

Government To Maintain 4% Tax Rate On Medicines

Industry / Spain With the aim of increasing government revenues (to cover the growth in public sector spending as a recession grips Spain) and decrease its budget deficit (forecast to equal to 8.1% of GDP in 2010), the...

October 2009

European Court Of Justice Requests European Commission To Reconsider Dual Pricing And Parallel Trade

Industry / Spain The European Court of Justice (ECJ) has said that EU antitrust regulators must reconsider their decision that drugmakers that prevent traders from exploiting price differences across Europe are restricting...

October 2009

Actavis Launches Generic Version Of Pfizer's Blockbuster Lipitor

Industry / Spain Iceland-based generic drugs manufacturer Actavis has launched a generic version of Pfizer's drug Lipitor (atorvastatin) in Spain. BMI believes that the launch of the off-patent cholesterol drug in Spain...

October 2009

Prescription-OTC Switching And Reluctance To Self-Medicate Hinders OTC Market Growth

Industry / Spain BMI calculates the Spanish over-the-counter (OTC) medicines market to have reached a value of EUR2.0bn (US$2.9bn) in 2008. By 2013 we expect this figure to reach EUR2.5bn (US$3.2bn), equating to a constant...

October 2009